CytoDyn, Inc. (CYDY)
| Market Cap | 1.82B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -159.18M |
| Shares Out | 577.95M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | 10.81 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $2.91 |
| Previous Close | $4.05 |
| Change ($) | -1.14 |
| Change (%) | -28.15% |
| Day's Open | 2.90 |
| Day's Range | 2.70 - 3.28 |
| Day's Volume | 21,344,379 |
| 52-Week Range | 0.81 - 10.01 |
12:48pm: Dow, Nasdaq headed in opposite directions The Dow was up 605 points, 1.9%, at 32,101 at midday, and the S&P 500 picked up 36 points, almost 1%, to 3,878 points. The Nasdaq, meanwhile,...
CytoDyn Inc (OTCQB:CYDY) said a Phase III trial of its leronlimab treatment, known as Vyrologix, for severe-to-critical patients with coronavirus (COVID-19) has demonstrated continued safety, ...
These trial results are currently being prepared to be submitted for publication
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA
VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...
VANCOUVER, Washington, March 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...
Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.
CytoDyn Inc (OTCQB:CYDY) announced Monday that study results have been unblinded from the CD12 trial of its drug Vyrologix (leronlimab or PRO-140) in coronavirus (COVID-19) patients, and the c...
CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks
CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines
CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation. Acute inflammation plays a major role in the hospitalizations and deaths of patien...
Correction to inclusion/exclusion criteria for eIND authorization
Manuscript entitled: “Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab,” by Nicholas J. Agresti, M.D.
The agency also provided specific guidance for inclusion/exclusion criteria for patients seeking leronlimab under eIND authorization
VANCOUVER, Washington, Dec. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140...
The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12
FDA's decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded
CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.
Overview of CytoDyn Inc. Focus on large molecule (biologic) Leronlimab, patient need, recent clinical trials, and competition for HIV indication.
CytoDyn is simultaneously finalizing an EUA application with the Philippine FDA with patient data from CD10 and recent eINDs for severe-to-critical patients
VANCOUVER, Washington, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140...
CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.
Preclinical results demonstrated leronlimab effectively inhibited fatty liver development
Vyrologix™ (leronlimab) has successfully replicated the CCR5 deficient phenotype in a pre-clinical animal study, and will now initiate HIV cure-focused clinical studies in collaboration with ...
Concurrently, CytoDyn is w orking d iligently with the FDA to initiate its Phase 2 COVID-19 Long Hauler T rial , with m ore than 100 volu n teers wanting to enroll
Rapid Enrollment Expected , As Many People Have Already Volunteered
Vyrologix is the proprietary name for leronli ma b
VANCOUVER, Washington, Nov. 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
VANCOUVER, Washington, Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
LOS ANGELES--(BUSINESS WIRE)---- $CYDY #CYDY--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc.
NEW YORK--(BUSINESS WIRE)-- #CYDY--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether CytoDyn, Inc. (“...
VANCOUVER, Washington, Nov. 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
Dr. Rahman's 18 years of pharmaceutical industry experience is highlighted by 16 successful BLA/NDAs and sBLAs
DSMC recommend s CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint
VANCOUVER, Washington, Oct. 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
VANCOUVER, Washington, Oct. 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...
VANCOUVER, Washington, Sept. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...
VANCOUVER, Washington, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...
VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles
CytoDyn: Bulls Continue To Get Torpedoed But The Thesis Remain Afloat
VANCOUVER, Washington, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...
U.S. FDA schedules Type A meeting with CytoDyn to discuss BLA filing for HIV
Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab
About CYDY
CytoDyn, a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement wi... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol CYDY |
Analyst Forecasts
The average 12-month stock price forecast for CytoDyn is 4.00, which is an increase of 37.46% from the latest price.